Cargando…

Natural Killer Cells in the Malignant Niche of Multiple Myeloma

Natural killer (NK) cells represent a subset of CD3- CD7+ CD56+/dim lymphocytes with cytotoxic and suppressor activity against virus-infected cells and cancer cells. The overall potential of NK cells has brought them to the spotlight of targeted immunotherapy in solid and hematological malignancies,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venglar, Ondrej, Bago, Julio Rodriguez, Motais, Benjamin, Hajek, Roman, Jelinek, Tomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787055/ https://www.ncbi.nlm.nih.gov/pubmed/35087536 http://dx.doi.org/10.3389/fimmu.2021.816499

Ejemplares similares

Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment
por: Motais, Benjamin, et al.
Publicado: (2021)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

A Bird’s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers
por: Motais, Benjamin, et al.
Publicado: (2020)

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma
por: Vdovin, Alexander, et al.
Publicado: (2022)

Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease
por: Charvátová, Sandra, et al.
Publicado: (2023)

Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
por: Mihályová, Jana, et al.
Publicado: (2021)

Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
por: Pittari, Gianfranco, et al.
Publicado: (2017)

P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS
por: Zihala, David, et al.
Publicado: (2023)

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
por: Chillemi, Antonella, et al.
Publicado: (2017)

Natural Killer Cells Modulation in Hematological Malignancies
por: Baier, Céline, et al.
Publicado: (2013)

Natural killer cells in non-hematopoietic malignancies
por: Desbois, Mélanie, et al.
Publicado: (2012)

Role of Natural Killer Cells in HIV-Associated Malignancies
por: Leal, Fabio E., et al.
Publicado: (2017)

Adaptive Features of Natural Killer Cells in Multiple Sclerosis
por: Moreira, Antía, et al.
Publicado: (2019)

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
por: Pittari, Gianfranco, et al.
Publicado: (2015)

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy
por: Besson, Laurie, et al.
Publicado: (2018)

Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Natural Killer Cells in Multiple Sclerosis: Entering the Stage
por: Beliën, Jarne, et al.
Publicado: (2022)

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies
por: Gismondi, Angela, et al.
Publicado: (2015)

Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review
por: Uppendahl, Locke D., et al.
Publicado: (2018)

The Role of Natural Killer Cells in Multiple Sclerosis and Their Therapeutic Implications
por: Chanvillard, Coralie, et al.
Publicado: (2013)

Extracellular vesicles derived from immortalized human natural killer cell line NK3.3 as a novel therapeutic for multiple myeloma
por: Matchett, Emily C., et al.
Publicado: (2023)

Natural Killers Are Made Not Born: How to Exploit NK Cells in Lung Malignancies
por: Carrega, Paolo, et al.
Publicado: (2017)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Natural Killer Cells in Asthma
por: Karimi, Khalil, et al.
Publicado: (2013)

Uterine Natural Killer Cells
por: Sojka, Dorothy K., et al.
Publicado: (2019)

Natural Killer Cells in the Lungs
por: Cong, Jingjing, et al.
Publicado: (2019)

From Natural Killer Cell Receptor Discovery to Characterization of Natural Killer Cell Defects in Primary Immunodeficiencies
por: Tabellini, Giovanna, et al.
Publicado: (2019)

Relative expression of receptors in uterine natural killer cells compared to peripheral blood natural killer cells
por: Ismail, Nurul Izza
Publicado: (2023)

Natural Killer Cells and Liver Fibrosis
por: Fasbender, Frank, et al.
Publicado: (2016)

Natural Killer Cells in Antifungal Immunity
por: Schmidt, Stanislaw, et al.
Publicado: (2017)

Unraveling Natural Killer T-Cells Development
por: Bennstein, Sabrina Bianca
Publicado: (2018)

Natural Killer T Cells in Cancer Immunotherapy
por: Nair, Shiny, et al.
Publicado: (2017)

Deciphering Natural Killer Cell Homeostasis
por: Pfefferle, Aline, et al.
Publicado: (2020)

Mechanosensation and Mechanotransduction in Natural Killer Cells
por: Santoni, Giorgio, et al.
Publicado: (2021)

Strategies to induce natural killer cell tolerance in xenotransplantation
por: Lopez, Kevin J., et al.
Publicado: (2022)

Multiple Levels of Chemokine Receptor Regulation in the Control of Mouse Natural Killer Cell Development
por: Bernardini, Giovanni, et al.
Publicado: (2014)

The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t3v8cpqlqu1adc10jm38a73iee